Journal
CELL HOST & MICROBE
Volume 29, Issue 1, Pages 13-22Publisher
CELL PRESS
DOI: 10.1016/j.chom.2020.12.011
Keywords
-
Categories
Funding
- NIH [F32 AI152296]
- Burroughs Wellcome Fund Postdoctoral Enrichment Program Award
- NIAID [AI106695, R01 AI107731, R01 AI125198]
Ask authors/readers for more resources
This review outlines the challenges and advantages of developing a safe, effective, and balanced DENV vaccine, with the aim of providing uniform protection against all four serotypes. While T cell biology plays an important role in establishing protective immunity, the review focuses on B cell responses. Understanding the immune correlates of protection against DENV infection is crucial for informing the development of a vaccine that can offer long-term, uniform protection.
More than 390 million human dengue virus (DENV) infections occur each year, worldwide. Dengvaxia, a live-virus tetravalent vaccine from Sanofi Pasteur, was recently approved for human clinical use, although vaccine performance against the four DENV serotypes is highly variable. Other dengue vaccines in advanced clinical testing also demonstrate variability in efficacy. In this review, we outline the benefits and challenges of developing a safe, effective, and balanced DENV vaccine that can provide uniform protection against all four serotypes. Even though T cell biology plays an important role in establishing protective immunity, this review focuses on B cell responses. We discuss the leading dengue vaccine candidates and review the specificity of antibody responses and the known immune correlates of protection against DENV infection. A better understanding of immune correlates of protection against DENV infection will inform the development of a vaccine that can provide long-term, uniform protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available